Financial Analysis: OPKO Health (NASDAQ:OPK) & Wellgistics Health (NASDAQ:MEDS)

Wellgistics Health (NASDAQ:MEDS – Get Free Report) and OPKO Health (NASDAQ:OPK – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Profitability

This table compares Wellgistics Health and OPKO Health’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Wellgistics Health -564.70% N/A -111.43%
OPKO Health -29.51% -10.90% -6.93%

Institutional & Insider Ownership

5.7% of Wellgistics Health shares are owned by institutional investors. Comparatively, 64.6% of OPKO Health shares are owned by institutional investors. 19.5% of Wellgistics Health shares are owned by company insiders. Comparatively, 44.7% of OPKO Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Wellgistics Health has a beta of -3.13, indicating that its share price is 413% less volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500.

Earnings and Valuation

This table compares Wellgistics Health and OPKO Health”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Wellgistics Health $23.34 million 0.10 -$101.28 million ($46.13) -0.02
OPKO Health $606.90 million 2.06 -$225.68 million ($0.19) -8.84

Wellgistics Health has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Wellgistics Health, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for Wellgistics Health and OPKO Health, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Wellgistics Health 1 0 0 0 1.00
OPKO Health 1 2 4 0 2.43

OPKO Health has a consensus price target of $3.42, suggesting a potential upside of 103.37%. Given OPKO Health’s stronger consensus rating and higher probable upside, analysts plainly believe OPKO Health is more favorable than Wellgistics Health.

Summary

OPKO Health beats Wellgistics Health on 11 of the 14 factors compared between the two stocks.

About Wellgistics Health

(Get Free Report)

Wellgistics Health is a U.S.-focused healthcare services and technology company centered on pharmaceutical distribution. It supplies prescription medicines, including branded and generic drugs, to pharmacies and other healthcare providers. The company also offers technology and services intended to support pharmacy purchasing, inventory management and connections among drug manufacturers, distributors and pharmacies. Its business is particularly oriented toward serving independent pharmacies. Wellgistics Health combines pharmaceutical wholesale distribution with technology-enabled pharmacy services.

About OPKO Health

(Get Free Report)

OPKO Health is a healthcare company with businesses in diagnostics and pharmaceuticals. Its diagnostic offerings have included BioReference Health laboratory services and the 4Kscore test, which helps assess the risk of aggressive prostate cancer. OPKO’s pharmaceutical products include Rayaldee, a prescription treatment for certain adults with chronic kidney disease and vitamin D insufficiency. The company also co-developed NGENLA, a long-acting growth hormone treatment for children with growth hormone deficiency, with Pfizer.

Receive News & Ratings for Wellgistics Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wellgistics Health and related companies with MarketBeat.com's FREE daily email newsletter.